Real-world evidence confirms high effectiveness of Pfizer-BioNTech COVID-19 vaccine

Data collected in Israel between 17 Jan and 6 March, when UK variant strain was dominant, suggest vaccine effectiveness (2 weeks after second dose) was at least 97% against symptomatic cases, severe and critical hospitalisations, and deaths, and 94% against asymptomatic cases.

Biospace Inc.